All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Future perspectives of ECP for GvHD treatment
By Ella Dixon
Featured
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The GvHD Hub was pleased to speak to Andrew Gennery, Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK, and Chair of the UK Photopheresis Society, about the future directions of extracorporeal photopheresis (ECP) for the treatment of GvHD.
Future perspectives of ECP for GvHD treatment
Gennery begins by providing a background to using ECP in pediatric patients, including the potential complications involved and how to mitigate these. He then discusses the process of ECP, including mechanism of action, treatment scheduling, and its efficacy in different types of GvHD.
Gennery goes on to speak about how the treatment landscape for GvHD has changed in the last 5 years, how it might change in the future, and where ECP fits in as an immunomodulatory agent. In the future, ECP may be combined with the newer immunosuppressive agents that are approved, or in development, for the treatment of GvHD to deliver positive outcomes for patients.
Key points
-
When using ECP in pediatric patients with low body weight, blood prime of the ECP machine prior to use can reduce the risk of hypotension.
-
Patients need to protect themselves from sunlight following ECP to avoid adverse effects.
-
ECP is an immunomodulatory process; this differs from most treatments for GvHD which are immunosuppressive. ECP leads to down-regulation of dendritic cells, down-regulation of activated T lymphocytes, and an increase in number of regulatory T cells.
-
In recent years, new agents have been licensed in GvHD, which has changed the treatment landscape. Clinical trials are needed to investigate the efficacy of combinations of ECP and newer agents, compared with these treatments alone.
Listen to this video as a podcast here:
Future perspectives of ECP for GvHD treatment
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox